 Robert Belknap
Concepts (156)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Latent Tuberculosis | 28 | 2024 | 70 | 8.120 |
Why?
| | Tuberculosis | 17 | 2024 | 283 | 4.220 |
Why?
| | Antitubercular Agents | 19 | 2024 | 208 | 3.970 |
Why?
| | Isoniazid | 14 | 2024 | 70 | 3.810 |
Why?
| | Rifampin | 12 | 2024 | 79 | 2.320 |
Why?
| | Mycobacterium tuberculosis | 7 | 2021 | 318 | 2.070 |
Why?
| | Directly Observed Therapy | 4 | 2021 | 15 | 1.640 |
Why?
| | Interferon-gamma Release Tests | 14 | 2024 | 32 | 1.620 |
Why?
| | Tuberculosis, Pulmonary | 4 | 2019 | 127 | 1.570 |
Why?
| | Tuberculin Test | 14 | 2024 | 36 | 1.410 |
Why?
| | Drug Therapy, Combination | 11 | 2024 | 1043 | 0.740 |
Why?
| | Mass Screening | 4 | 2020 | 1354 | 0.730 |
Why?
| | Sputum | 3 | 2019 | 302 | 0.680 |
Why?
| | Tuberculosis, Multidrug-Resistant | 2 | 2019 | 47 | 0.640 |
Why?
| | Drug Administration Schedule | 6 | 2021 | 781 | 0.610 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 107 | 0.560 |
Why?
| | Rifamycins | 1 | 2018 | 6 | 0.560 |
Why?
| | Medication Adherence | 3 | 2018 | 540 | 0.560 |
Why?
| | Emigrants and Immigrants | 3 | 2020 | 157 | 0.520 |
Why?
| | Self Administration | 1 | 2017 | 122 | 0.510 |
Why?
| | HIV Infections | 7 | 2024 | 3186 | 0.430 |
Why?
| | Early Diagnosis | 1 | 2016 | 251 | 0.430 |
Why?
| | Health Personnel | 2 | 2019 | 749 | 0.430 |
Why?
| | Immunologic Factors | 1 | 2016 | 260 | 0.420 |
Why?
| | Drug Monitoring | 2 | 2018 | 399 | 0.400 |
Why?
| | Humans | 47 | 2024 | 145140 | 0.380 |
Why?
| | Reagent Kits, Diagnostic | 2 | 2019 | 33 | 0.380 |
Why?
| | Osteomyelitis | 2 | 2012 | 144 | 0.370 |
Why?
| | Diabetic Foot | 1 | 2012 | 25 | 0.360 |
Why?
| | Limb Salvage | 1 | 2012 | 73 | 0.360 |
Why?
| | United States | 11 | 2023 | 16065 | 0.350 |
Why?
| | Proteome | 1 | 2016 | 512 | 0.350 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1579 | 0.350 |
Why?
| | Penicillin G | 1 | 2011 | 7 | 0.340 |
Why?
| | Streptomycin | 1 | 2011 | 18 | 0.340 |
Why?
| | Biosensing Techniques | 1 | 2013 | 140 | 0.330 |
Why?
| | Enterococcus faecalis | 1 | 2011 | 29 | 0.330 |
Why?
| | Students | 1 | 2016 | 650 | 0.320 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2011 | 71 | 0.310 |
Why?
| | Proteomics | 1 | 2016 | 1185 | 0.300 |
Why?
| | Anti-Infective Agents | 1 | 2012 | 232 | 0.300 |
Why?
| | Bacteremia | 1 | 2011 | 222 | 0.280 |
Why?
| | Sensitivity and Specificity | 5 | 2020 | 1995 | 0.270 |
Why?
| | Clostridium butyricum | 1 | 2008 | 2 | 0.270 |
Why?
| | Clostridium Infections | 1 | 2008 | 74 | 0.250 |
Why?
| | Renal Dialysis | 1 | 2011 | 466 | 0.250 |
Why?
| | Adult | 16 | 2024 | 40665 | 0.240 |
Why?
| | Biomarkers | 1 | 2016 | 4282 | 0.220 |
Why?
| | Anti-Bacterial Agents | 5 | 2013 | 1922 | 0.210 |
Why?
| | Female | 20 | 2024 | 78636 | 0.210 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2020 | 1742 | 0.210 |
Why?
| | Middle Aged | 14 | 2023 | 36126 | 0.200 |
Why?
| | Staphylococcal Infections | 3 | 2013 | 390 | 0.180 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2023 | 261 | 0.180 |
Why?
| | Fractures, Open | 2 | 2013 | 28 | 0.180 |
Why?
| | Male | 17 | 2024 | 72664 | 0.180 |
Why?
| | Sepsis | 1 | 2008 | 662 | 0.170 |
Why?
| | Health Systems Plans | 1 | 2020 | 3 | 0.160 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2005 | 1216 | 0.160 |
Why?
| | Adolescent | 9 | 2021 | 22479 | 0.160 |
Why?
| | Treatment Failure | 2 | 2018 | 360 | 0.150 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2019 | 39 | 0.140 |
Why?
| | Self Report | 1 | 2023 | 867 | 0.140 |
Why?
| | Substance-Related Disorders | 1 | 2008 | 1093 | 0.140 |
Why?
| | Urban Health Services | 1 | 2018 | 68 | 0.140 |
Why?
| | Antibodies, Monoclonal | 1 | 2005 | 1505 | 0.130 |
Why?
| | Uganda | 3 | 2024 | 89 | 0.130 |
Why?
| | Antibiotics, Antitubercular | 1 | 2017 | 35 | 0.130 |
Why?
| | Prospective Studies | 6 | 2024 | 8035 | 0.130 |
Why?
| | Public Health | 2 | 2013 | 571 | 0.130 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2016 | 37 | 0.120 |
Why?
| | Reminder Systems | 1 | 2017 | 140 | 0.120 |
Why?
| | Comorbidity | 2 | 2019 | 1657 | 0.120 |
Why?
| | Retrospective Studies | 5 | 2021 | 17247 | 0.120 |
Why?
| | False Positive Reactions | 2 | 2014 | 123 | 0.110 |
Why?
| | Odds Ratio | 1 | 2018 | 1082 | 0.110 |
Why?
| | Host-Pathogen Interactions | 1 | 2018 | 361 | 0.110 |
Why?
| | Child, Preschool | 5 | 2021 | 11835 | 0.110 |
Why?
| | Aged | 6 | 2021 | 26096 | 0.110 |
Why?
| | Text Messaging | 1 | 2017 | 182 | 0.110 |
Why?
| | Urban Population | 1 | 2018 | 492 | 0.110 |
Why?
| | Population Surveillance | 1 | 2018 | 484 | 0.100 |
Why?
| | Young Adult | 5 | 2019 | 14176 | 0.100 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2018 | 438 | 0.100 |
Why?
| | Universities | 1 | 2016 | 443 | 0.100 |
Why?
| | Vancomycin | 1 | 2013 | 94 | 0.090 |
Why?
| | Prosthesis-Related Infections | 1 | 2013 | 98 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2018 | 11741 | 0.090 |
Why?
| | Infant | 3 | 2020 | 10060 | 0.090 |
Why?
| | Debridement | 1 | 2012 | 85 | 0.090 |
Why?
| | Infusions, Intravenous | 2 | 2011 | 428 | 0.090 |
Why?
| | Mycobacterium leprae | 1 | 2010 | 9 | 0.080 |
Why?
| | Leprosy | 1 | 2010 | 25 | 0.080 |
Why?
| | Risk Assessment | 2 | 2019 | 3740 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2023 | 419 | 0.080 |
Why?
| | Glycolipids | 1 | 2010 | 53 | 0.080 |
Why?
| | Risk Factors | 4 | 2018 | 10857 | 0.080 |
Why?
| | Administration, Oral | 1 | 2013 | 862 | 0.080 |
Why?
| | Drug Synergism | 1 | 2011 | 354 | 0.080 |
Why?
| | Antibiotic Prophylaxis | 1 | 2011 | 134 | 0.080 |
Why?
| | Antibodies, Bacterial | 1 | 2010 | 147 | 0.080 |
Why?
| | Antigens, Bacterial | 1 | 2010 | 126 | 0.080 |
Why?
| | Infant, Newborn | 2 | 2018 | 6435 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2012 | 1264 | 0.070 |
Why?
| | Follow-Up Studies | 3 | 2018 | 5411 | 0.070 |
Why?
| | Orthopedics | 1 | 2011 | 170 | 0.070 |
Why?
| | Feasibility Studies | 1 | 2013 | 1109 | 0.070 |
Why?
| | Child | 4 | 2019 | 22670 | 0.070 |
Why?
| | Age Distribution | 1 | 2008 | 402 | 0.070 |
Why?
| | Primary Health Care | 1 | 2018 | 1725 | 0.060 |
Why?
| | Lipopolysaccharides | 1 | 2010 | 858 | 0.060 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 451 | 0.060 |
Why?
| | Substance Abuse, Intravenous | 1 | 2008 | 127 | 0.060 |
Why?
| | Catheterization, Central Venous | 1 | 2008 | 123 | 0.060 |
Why?
| | Incidence | 2 | 2013 | 2915 | 0.060 |
Why?
| | Infliximab | 1 | 2005 | 111 | 0.050 |
Why?
| | Tuberculin | 1 | 2024 | 8 | 0.050 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1506 | 0.050 |
Why?
| | Mycobacterium avium | 1 | 2004 | 21 | 0.050 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 19 | 0.050 |
Why?
| | Body Mass Index | 1 | 2013 | 2437 | 0.050 |
Why?
| | Anti-HIV Agents | 1 | 2011 | 908 | 0.050 |
Why?
| | Peritonitis | 1 | 2004 | 83 | 0.050 |
Why?
| | Mycobacterium avium-intracellulare Infection | 1 | 2004 | 63 | 0.050 |
Why?
| | Cohort Studies | 1 | 2012 | 5988 | 0.040 |
Why?
| | Equivalence Trials as Topic | 1 | 2020 | 35 | 0.040 |
Why?
| | HIV | 1 | 2021 | 251 | 0.040 |
Why?
| | Pragmatic Clinical Trials as Topic | 1 | 2020 | 132 | 0.040 |
Why?
| | Specimen Handling | 1 | 2021 | 182 | 0.040 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Models, Theoretical | 1 | 2020 | 556 | 0.030 |
Why?
| | Arthritis, Rheumatoid | 1 | 2005 | 1174 | 0.030 |
Why?
| | Colorado | 2 | 2018 | 4538 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2018 | 500 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2115 | 0.030 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2026 | 0.020 |
Why?
| | Premedication | 1 | 2013 | 45 | 0.020 |
Why?
| | Prevalence | 1 | 2020 | 2855 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2021 | 1993 | 0.020 |
Why?
| | Disease Progression | 1 | 2019 | 2857 | 0.020 |
Why?
| | Drug Discovery | 1 | 2012 | 153 | 0.020 |
Why?
| | Fracture Fixation, Internal | 1 | 2013 | 213 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2018 | 3616 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2011 | 177 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 847 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1177 | 0.020 |
Why?
| | Pilot Projects | 1 | 2013 | 1889 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1368 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2949 | 0.010 |
Why?
| | Pregnancy | 1 | 2018 | 7182 | 0.010 |
Why?
| | Mice | 1 | 2021 | 18303 | 0.010 |
Why?
| | Immunocompetence | 1 | 2004 | 46 | 0.010 |
Why?
| | Cross-Sectional Studies | 1 | 2014 | 5886 | 0.010 |
Why?
| | Time Factors | 1 | 2010 | 7107 | 0.010 |
Why?
| | Animals | 1 | 2021 | 37952 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2928 | 0.010 |
Why?
|
|
Belknap's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|